| Name | Title | Contact Details |
|---|
InfoBeyond – Advanced in Cybersecurity, Deep Learning, Blockchain, and Big Data Streaming
We make it easy for retailers to collect customer data and activate it through loyalty programs and personalized offers.
Embrace is a mobile observability and data platform that empowers companies to deliver optimal mobile experiences by collecting comprehensive session level data for each and every user experience.
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.
0 K SATISFIED CUSTOMERS 125 K SATISFIED CUSTOMERS 0 Million TICKETS PROCESSED ANNUALLY 15 Million TICKETS PROCESSED ANNUALLY 0 K TICKETS PROCESSED THIS WEEK 400 K TICKETS PROCESSED THIS WEEK Our Solutions The LOGiX™ Platform Our Continuous Intelligence...